Boehringer Ingelheim Corporation Release: New European Survey Highlights Ischaemic Stroke Protection as Treatment Priority for Patients With Atrial Fibrillation
5/28/2013 11:21:54 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
New findings from a pan-European online survey of 1,000 physicians have demonstrated that for over two thirds of physicians, preventing ischaemic stroke is the most important treatment goal for patients with atrial fibrillation (AF).1 Ischaemic stroke is the most common type of stroke suffered by patients with AF2, and as such physicians across Europe have highlighted the vital need for increased awareness of the true incidence and impact in this patient population. The survey findings were announced in parallel with the European Stroke Conference in London (28th-31st May) and highlight the need for additional information and education about the risk and impact of ischaemic stroke on the lives of AF patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by